Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) monoclonal antibody, TZLS-501.
On September 25, 2025, Tiziana Life Sciences announced plans to advance its second asset, TZLS-501, a fully human anti-IL-6 receptor monoclonal antibody. This decision comes amid increased industry ...
- CX-904 is CytomX’s first T-cell-engaging bispecific antibody and the sixth Probody® therapeutic candidate to enter the clinic - SOUTH SAN FRANCISCO, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- CytomX ...
SOUTH SAN FRANCISCO, Calif. and MONROVIA, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel ...
Tiziana Life Sciences Ltd. (NASDAQ: TLSA) recently announced the Company has initiated site selection for its lead intranasal anti-CD3 monoclonal antibody drug candidate “foralumab” program entering ...
This month, Tiziana Life Sciences TLSA expects to start enrolling patients for a phase 2a trial of Foralumab, an immunomodulation therapy for Secondary Progressive Multiple Sclerosis (SPMS) that’s ...
Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study Healthy volunteers were recruited and underwent ...
The National Institute for Health and Care Excellence (NICE) has published final draft guidance recommending elranatamab (Elrexfio) for the treatment of multiple myeloma. NICE has now lifted these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback